Lentiviral vectors for the treatment of primary immunodeficiencies
- 1.2k Downloads
In the last years important progress has been made in the treatment of several primary immunodeficiency disorders (PIDs) with gene therapy. Hematopoietic stem cell (HSC) gene therapy indeed represents a valid alternative to conventional transplantation when a compatible donor is not available and recent success confirmed the great potential of this approach. First clinical trials performed with gamma retroviral vectors were promising and guaranteed clinical benefits to the patients. On the other hand, the outcome of severe adverse events as the development of hematological abnormalities highlighted the necessity to develop a safer platform to deliver the therapeutic gene. Self-inactivating (SIN) lentiviral vectors (LVVs) were studied to overcome this hurdle through their preferable integration pattern into the host genome. In this review, we describe the recent advancements achieved both in vitro and at preclinical level with LVVs for the treatment of Wiskott-Aldrich syndrome (WAS), chronic granulomatous disease (CGD), ADA deficiency (ADA-SCID), Artemis deficiency, RAG1/2 deficiency, X-linked severe combined immunodeficiency (γchain deficiency, SCIDX1), X-linked lymphoproliferative disease (XLP) and immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome.
- Brendel C, Muller-Kuller U, Schultze-Strasser S et al (2011) Physiological regulation of transgene expression by a lentiviral vector containing the A2UCOE linked to a myeloid promoter. Gene Ther 24(3):1018–1029Google Scholar
- Carbonaro DA, Zhang L, Jin X, et al (2013) Pre-clinical demonstration of lentiviral vector mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther doi:10.1038/mt.2013.265
- Griffith LM, Cowan MJ, Notarangelo LD et al (2013) Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol doi:10.1016/j.jaci.2013.07.052.
- Holland SM (2013) Chronic granulomatous disease. Hematol Oncol Clin North Am 27(1):89–99, viii. doi:10.1016/j.hoc.2012.11.002
- Moratto D, Giliani S, Bonfim C et al (2011) Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 118(6):1675–1684PubMedCentralPubMedCrossRefGoogle Scholar
- Seger RA (2010) Advances in the diagnosis and treatment of chronic granulomatous disease. Curr Opin Hematol Nov 11. [Epub ahead of print]Google Scholar